Trius Therapeutics, (FRA:TEU) Machinery, Furniture, Equipment : €0.00 Mil (As of Jun. 2013)

Trius Therapeutics, Inc., was incorporated in California in June 2004. It is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious infections. The Company is developing tedizolid phosphate, a new, novel antibiotic, for the treatment of serious Gram-positive bacterial infections, including those caused by methicillin-resistant staphylococcus aureus, or MRSA. Tedizolid phosphate is being developed for acute bacterial skin and skin structure infections, or ABSSSI, and pneumonia, and potentially for other indications. ABSSSI is the current classification for complicated skin and skin structure infections. In addition, the company is discovering antibiotics for infections caused by Gram-negative bacteria using its structure based discovery platform. In December 2011, it reported top line data from its first Phase 3 clinical trial, the ESTABLISH 1 (TR701-112) study, of the oral dosage form of tedizolid phosphate for the treatment of ABSSSI. All primary and secondary endpoints for the ESTABLISH 1 study were achieved. In December 2012, the company completed enrollment in its second Phase 3 clinical trial, the ESTABLISH 2 (TR701-113) study, of the intravenous to oral transition therapy for the treatment of ABSSSI. Its current development efforts are focused on developing tedizolid phosphate (formerly known as torezolid phosphate), an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. Its strategy is to discover and develop a pipeline of antibiotics focused on the treatment of life-threatening infections, consisting of tedizolid phosphate and additional compounds discovered internally using its proprietary discovery platform. The Company employs the services of Albany Molecular Research Incorporated to produce tedizolid phosphate API and Patheon, Inc., or Patheon, to produce the solid oral and sterile IV tedizolid phosphate finished products. It currently employs internal resources and third-party consultants to manage its manufacturing contractors. Its competitors include large pharmaceutical and biotechnology companies, specialty pharmaceutical and generic drug companies, academic institutions, government agencies and research institutions. The Company is subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of its products to the extent it choose to sell any products outside of the United States.